Expediting Drug Development for Pediatric Inflammatory Bowel Disease: A Workshop to Identify Barriers and Move Forward
Authors:
- 1 January 2022
- journal article
- editorial
- Published by Elsevier in Gastroenterology
- Vol. 162 (1) , 22-25
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Subcutaneous Golimumab in Pediatric Ulcerative ColitisInflammatory Bowel Diseases, 2017
- Long-term outcomes of pediatric inflammatory bowel diseaseSeminars in Pediatric Surgery, 2017
- Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative DatabasesAmerican Journal of Gastroenterology, 2017
- The incidence of inflammatory bowel disease in Denmark 1980–2013: a nationwide cohort studyAlimentary Pharmacology & Therapeutics, 2017
- Changing Age Demographics of Inflammatory Bowel Disease in Ontario, CanadaInflammatory Bowel Diseases, 2014
- Incidence, Outcomes, and Health Services Burden of Very Early Onset Inflammatory Bowel DiseaseGastroenterology, 2014
- Highlights in IBD Epidemiology and Its Natural History in the Paediatric AgeGastroenterology Research and Practice, 2013
- Pharmacokinetics of Infliximab in Children with Moderate-to-Severe Ulcerative ColitisInflammatory Bowel Diseases, 2013
- Safety and Efficacy of Adalimumab for Moderate to Severe Crohn's Disease in ChildrenGastroenterology, 2012
- Epidemiology of pediatric inflammatory bowel disease: A systematic review of international trendsInflammatory Bowel Diseases, 2011